FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Palumbo, A. [1 ]
Magarotto, V. [1 ]
Sonneveld, P. [2 ]
Plesner, T. [3 ]
Paba-Prada, C. [4 ]
Voorhees, P. [5 ]
Mellqvist, U. H. [6 ]
Byrne, C. [7 ]
Harmenberg, J. [8 ]
Nordstrom, E. [9 ]
Zubair, H. [8 ]
Richardson, P. G. [4 ]
机构：
[1] Univ Turin, Dept Oncol, Myeloma Unit, Div Hematol, Turin, Italy
[2] Erasmus MC, Rotterdam, Netherlands
[3] Vejle Hosp, Hematol, Vejle, Denmark
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ N Carolina, Chapel Hill, NC USA
[6] Sodra Alvsborgs Sjukhus, Boras, Sweden
[7] Oncopeptides AB, Miami, FL USA
[8] Oncopeptides AB, Stockholm, Sweden
[9] Oncopeptides AB, Clin, Stockholm, Sweden
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P281
引用
收藏
页码：85 / 85
页数：1
相关论文
共 50 条
  • [1] AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mellqvist, U. H.
    Paba-Prada, C.
    Palumbo, A.
    Plesner, T.
    Sonneveld, P.
    Voorhees, P.
    Byrne, C.
    Harmenberg, J.
    Nordstrom, E.
    Richardson, P. G.
    HAEMATOLOGICA, 2014, 99 : 375 - 376
  • [2] ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE 1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND *DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA
    Magarotto, V.
    Sonneveld, P.
    Voorhees, P.
    Paba-Prada, C.
    Plesner, T.
    Mellqvist, U. H.
    Byrne, C.
    Harmenberg, J.
    Nordstrom, E.
    Palumbo, A.
    Richardson, P.
    HAEMATOLOGICA, 2015, 100 : 89 - 89
  • [3] Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)
    Paba-Prada, Claudia
    Palumbo, Antonio
    Mellqvist, Ulf-Henrik
    Voorhees, Peter M.
    Plesner, Torben
    Sonneveld, Pieter
    Byrne, Catriona
    Harmenberg, Johan
    Nordstrom, Eva
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [4] Oncopeptides Presents New Combination Data on Melflufen in Relapsed and Refractory Multiple Myeloma (RRMM)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (09)
  • [5] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
  • [6] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
  • [7] Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Moreb, Jan S.
    Anderson, Kenneth C.
    Laubach, Jacob P.
    Thuresson, Sara
    Thuresson, Marcus
    Byrne, Catriona
    Harmenberg, Johan
    Bakker, Nicolaas A.
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) : 757 - +
  • [8] ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
    Ocio, Enrique M.
    Efebera, Yvonne A.
    Hajek, Roman
    Straub, Jan
    Maisnar, Vladimir
    Eveillard, Jean-Richard
    Karlin, Lionel
    Mateos, Maria -Victoria
    Oriol, Albert
    Ribrag, Vincent
    Richardson, Paul G.
    Norin, Stefan
    Obermueller, Jakob
    Bakker, Nicolaas A.
    Pour, Ludek
    HAEMATOLOGICA, 2024, 109 (03) : 867 - 876
  • [9] Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Bringhen, Sara
    Richardson, Paul G.
    Voorhees, Peter Michael
    Plesner, Torben
    Mellqvist, Ulf-Henrik
    Zonder, Jeffrey A.
    Reeves, Brandi Nikcole
    Zavisic, Stojan
    Harmenberg, Johan
    Obermueller, Jakob
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide
    Sonneveld, Pieter
    Schjesvold, Fredrik
    Robak, Pawel
    Rossjey, Viktor
    Pour, Ludk
    Minarik, Jiri
    Delimpasi, Sosana
    Legic, Wojciech
    Salogub, Galina
    Harmenberg, Johan
    Byrne, Catriona
    Nordstrom, Eva
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S25 - S25
12345